Double-blind test program for astrometric planet detection with Gaia

We use detailed simulations of the Gaia observations of synthetic planetary systems and develop and utilize independent software codes in double-blind mode to analyze the data, including statistical tools for planet detection and different algorithms for single and multiple Keplerian orbit fitting that use no a priori knowledge of the true orbital parameters of the systems. 1) Planets with astrometric signatures $\alpha\simeq 3$ times the single-measurement error $\sigma_\psi$ and period $P\leq 5$ yr can be detected reliably, with a very small number of false positives. 2) At twice the detection limit, uncertainties in orbital parameters and masses are typically $15$. 3) Over 70% of two-planet systems with well-separated periods in the range $0.2\leq P\leq 9$ yr, $2\leq\alpha/\sigma_\psi\leq 50$, and eccentricity $e\leq 0.6$ are correctly identified. 4) Favorable orbital configurations have orbital elements measured to better than 10% accuracy $> 90$ of the time, and the value of the mutual inclination angle determined with uncertainties \leq 10^{\degr}. 5) Finally, uncertainties obtained from the fitting procedures are a good estimate of the actual errors. Extrapolating from the present-day statistical properties of the exoplanet sample, the results imply that a Gaia with $\sigma_\psi$ = 8 $\mu$as, in its unbiased and complete magnitude-limited census of planetary systems, will measure several thousand giant planets out to 3-4 AUs from stars within 200 pc, and will characterize hundreds of multiple-planet systems, including meaningful coplanarity tests. Finally, we put Gaia into context, identifying several areas of planetary-system science in which Gaia can be expected to have a relevant impact, when combined with data coming from other ongoing and future planet search programs.Comment: 32 pages, 24 figures, 6 tables. Accepted for pubolication in A&

Detection and Characterization of Planetary Systems with μ\muas Astrometry

Astrometry as a technique has so far proved of limited utility when employed as either a follow-up tool or to independently search for planetary mass companions orbiting nearby stars. However, this is bound to change during the next decade. In this review, I start by summarizing past and present efforts to detect planets via milli-arcsecond astrometry. Next, I provide an overview of the variety of technical, statistical, and astrophysical challenges that must be met by future ground-based and space-borne efforts in order to achieve the required degree of astrometric measurement precision. Then, I discuss the planet-finding capabilities of future astrometric observatories aiming at micro-arcsecond precision, with a particular focus on their ability to fully describe multiple-component systems. I conclude by putting astrometry in context, illustrating its potential for important contributions to planetary science, as a complement to other indirect and direct methods for the detection and characterization of planetary systems.Comment: 22 pages, 4 figures. Invited contribution at the conference Extrasolar Planets in Multi-Body Systems: Theory and Observations (Torun, Poland, August 25-29, 2008). To appear in the European Astronomical Society Publication Serie

Publisher Correction: The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia.

An amendment to this paper has been published and can be accessed via a link at the top of the paper

Author Correction: The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia.

An amendment to this paper has been published and can be accessed via a link at the top of the paper

Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register

Diabetes is an increasing global health burden with the highest prevalence (24.0%) observed in elderly people. Older diabetic adults have a greater risk of hospitalization and several geriatric syndromes than older nondiabetic adults. For these conditions, special care is required in prescribing therapies including anti- diabetes drugs. Aim of this study was to evaluate the appropriateness and the adherence to safety recommendations in the prescriptions of glucose-lowering drugs in hospitalized elderly patients with diabetes. Data for this cross-sectional study were obtained from the REgistro POliterapie-Società Italiana Medicina Interna (REPOSI) that collected clinical information on patients aged ≥ 65 years acutely admitted to Italian internal medicine and geriatric non-intensive care units (ICU) from 2010 up to 2019. Prescription appropriateness was assessed according to the 2019 AGS Beers Criteria and anti-diabetes drug data sheets.Among 5349 patients, 1624 (30.3%) had diagnosis of type 2 diabetes. At admission, 37.7% of diabetic patients received treatment with metformin, 37.3% insulin therapy, 16.4% sulfonylureas, and 11.4% glinides. Surprisingly, only 3.1% of diabetic patients were treated with new classes of anti- diabetes drugs. According to prescription criteria, at admission 15.4% of patients treated with metformin and 2.6% with sulfonylureas received inappropriately these treatments. At discharge, the inappropriateness of metformin therapy decreased (10.2%, P < 0.0001). According to Beers criteria, the inappropriate prescriptions of sulfonylureas raised to 29% both at admission and at discharge. This study shows a poor adherence to current guidelines on diabetes management in hospitalized elderly people with a high prevalence of inappropriate use of sulfonylureas according to the Beers criteria

Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia

In the past decade, novel targeted therapy approaches, such as BTK inhibitors and Bcl2 blockers, and innovative treatments that regulate the immune response against cancer cells, such as monoclonal antibodies, CAR-T cell therapy, and immunomodulatory molecules, have been established to provide support for the treatment of patients. However, drug resistance development and relapse are still major challenges in CLL treatment. Several studies revealed that non-coding RNAs have a main role in the development and progression of CLL. Specifically, microRNAs (miRs) and tRNA-derived small-RNAs (tsRNAs) were shown to be outstanding biomarkers that can be used to diagnose and monitor the disease and to possibly anticipate drug resistance and relapse, thus supporting physicians in the selection of treatment regimens tailored to the patient needs. In this review, we will summarize the most recent discoveries in the field of targeted therapy and immunotherapy for CLL and discuss the role of ncRNAs in the development of novel drugs and combination regimens for CLL patients

The Glucose-Regulated MiR-483-3p Influences Key Signaling Pathways in Cancer

The hsa-mir-483 gene, located within the IGF2 locus, transcribes for two mature microRNAs, miR-483-5p and miR-483-3p. This gene, whose regulation is mediated by the the CTNNB1/USF1 complex, shows an independent expression from its host gene IGF2. The miR-483-3p affects the Wnt/β-catenin, the TGF-β, and the TP53 signaling pathways by targeting several genes as CTNNB1, SMAD4, IGF1, and BBC3. Accordingly, miR-483-3p is associated with various tissues specific physiological properties as insulin and melanin production, as well as with cellular physiological functions such as wounding, differentiation, proliferation, and survival. Deregulation of miR-483-3p is observed in different types of cancer, and its overexpression can inhibit the pro-apoptotic pathway induced by the TP53 target effectors. As a result, the oncogenic characteristics of miR-483-3p are linked to the effect of some of the most relevant cancer-related genes, TP53 and CTNNB1, as well as to one of the most important cancer hallmark: the aberrant glucose metabolism of tumor cells. In this review, we summarize the recent findings regarding the miR-483-3p, to elucidate its functional role in physiological and pathological contexts, focusing overall on its involvement in cancer and in the TP53 pathway

POLYCYCLIC AROMATIC HYDROCARBONS (PAHS) IN SEAFOODS CAUGHT IN CORIGLIANO CALABRO GULF (CS,ITALY)

Polycyclic aromatic hydrocarbons (PAHs) were determined by high performance liquid chromatography (HPLC) with fluorescence detection in seafoods (Merluccius merluccius, Arnoglossus laterna, Scomber japonicus, Penaeus kerathurus, Eledone cirrhosa) collected along coasts of Corigliano Calabro gulf (Calabria Region - Italy). The results showed that Bap levels exceeded the limit fixed by EU Regulation 1881/2006 in only four samples of Merluccius merluccius, Arnoglossus laterna and Scomber japonicus particularly. PAH concentrations detected in samples caught in winter were higher than those found in summer